Found: 20
Select item for more details and to access through your institution.
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
- Published in:
- Cancer Immunology, Immunotherapy, 2009, v. 58, n. 1, p. 95, doi. 10.1007/s00262-008-0529-y
- By:
- Publication type:
- Article
Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 4, p. 459, doi. 10.1007/s00262-006-0218-7
- By:
- Publication type:
- Article
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 7, p. 785, doi. 10.1007/s00262-005-0082-x
- By:
- Publication type:
- Article
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 5, p. 503, doi. 10.1007/s00262-005-0001-1
- By:
- Publication type:
- Article
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
- Published in:
- International Journal of Cancer, 2002, v. 100, n. 6, p. 690, doi. 10.1002/ijc.10557
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259036
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.24187
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.120.241877
- By:
- Publication type:
- Article
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.
- Published in:
- PEDS: Protein Engineering, Design & Selection, 2006, v. 19, n. 10, p. 461, doi. 10.1093/protein/gzl031
- By:
- Publication type:
- Article